Belgium's Galapagos NV has bought out Sareum's assets in drug discovery services for 695,000 euros. The assets will help position Galapagos' service division, BioFocus DPI, in the structure-based drug discovery field. In structure-based drug design, the three-dimensional structure of a drug target is used to guide the discovery of small molecules.
"We are pleased to have acquired Sareum's structure-based drug discovery assets and welcome their team and their clients to BioFocus DPI," said Dr. Chris Newton, senior vice president, BioFocus DPI. "The assets and expertise acquired from Sareum strengthen our drug discovery, adding a novel technology that our customers are expressing interest in. We look forward to extending and expanding this business within the BioFocus DPI client base."
- check out the press release